Evidence map›Paper›PMID 41357389›Full record

ArticleWorld journal of transplantation2025

Middle- and long-term survival of patients with heart transplant in Mexico from 1988 to 2023: A group experience.

Guillermo Careaga-Reyna, Hugo Jesus Zetina-Tun

Abstract read
In one paragraph

Article in World journal of transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Guillermo Careaga-ReynaMedical Attention Unit, Instituto Mexicano del Seguro Social, Mexico City 06600, Ciudad de México, Mexico. gcareaga3@gmail.com.
Hugo Jesus Zetina-TunHeart Transplant Clinic, Unidad Médica de Alta Especialidad General Hospital "Dr. Gaudencio González Garza" of the Centro Medico Nacional "La Raza", Instituto Mexicano del Seguro Social, Mexico City 02990, Ciudad de México, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHeart transplantation is the last and best option for end-stage heart failure management. Early mortality rates have significantly decreased, enabling patients to survive longer with fewer complications, a trend observed even in our setting. The primary shared challenge has centered on achieving surgical success and immediate survival. The question arises about the medium- and long-term survival of patients with heart transplant in Mexico.

aimTo present the results of the medium and long-term follow-up of heart transplant patients.

methodsThis was a retrospective study of a single medical unit, and we selected patients who received heart transplants from July 21, 1988 to September 30, 2023. Selection criteria encompassed age, sex, and primary indication for heart transplantation across all groups. Patients with incomplete information or who died within 30 postoperative days were excluded. Data of primary pathology, ischemic, extracorporeal circulation, aortic cross-clamping times, length of ventilatory support, stay in postoperative therapy, hospitalization, and functional class were analyzed.

resultsThe causes of morbidity, mortality, and percentage of survival at 1, 5, and 10 years were examined. Overall, 257 heart transplants were performed during the study period. Of the total cases, 22 with incomplete data and 47 who died within 30 postoperative days were excluded for the middle- and long-term survival analyses. Of the remaining 188 patients, heart transplantation was performed (males: 146, females: 42). The average age of the participants was 44.43 ± 14.48 years. The primary indications included ischemic cardiomyopathy (42.55%) and dilated cardiomyopathy (39.36%). The mean durations of mechanical ventilator support, intensive care stay, and hospital stay were 57.55 ± 103.50 hours, 9.96 ± 8.59 days, and 19.49 ± 18.23 days, respectively. One-, five-, and ten-year survival rates were 90.7%, 71.3%, and 60.3%, respectively. Of the patients, 94% and 6% were in functional classes I and II, respectively. Infection and neurological hemorrhagic or ischemic stroke (26%) were the main causes of mortality in the first year. Subsequently, chronic rejection manifesting as graft vasculopathy increased in frequency (30%).

conclusionIn our setting, heart transplantation yields medium- and long-term survival and quality of life outcomes comparable to those achieved by other international centers.

Indexed as

Graft vasculopathyHeart transplantationImmunosuppressionRejection reactionSurvival

Identifiers

PMID41357389
PMCPMC12679199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.